View More Recent Stories
-
Natera (NTRA) PT Raised to $200 at TD Cowen Following Sales Beat
-
Natera (NTRA) Tops Q1 EPS by 14c, provides guidance
-
Natera (NTRA) Announces Broad Clinical Launch of Ultra-Sensitive Signatera Genome MRD Test
-
Increasing unusual put option volume: TKO LW NTRA XLI JNPR KBE
-
TD Cowen: 'Top 10 Themes Coming Out of 45th Annual Health Care Conference'
-
Natera (NTRA) Announces Enrollment of First Patients in the HEROES Clinical Trial in Metastatic HER2+ Breast Cancer
-
TD Cowen on Natera (NTRA): '2025 Guide Hits on Many Fronts, Setting Up for Another Strong Year'
-
Natera (NTRA) PT Raised to $195 at Canaccord Genuity
-
Natera (NTRA) Tops Q4 EPS by 8c, provides guidance
-
Natera (NTRA) Announces Medicare Coverage of Signatera for Surveillance in Lung Cancer
-
Canaccord Genuity Reiterates Buy Rating on Natera (NTRA)
-
Raymond James Reiterates Outperform Rating on Natera (NTRA)
-
Canaccord Genuity Reiterates Buy Rating on Natera (NTRA)
-
Barclays Starts Natera (NTRA) at Overweight
-
Natera (NTRA): Court Grants Natera’s Request to Include Additional Patent in its Lawsuit Against NeoGenomics
-
Natera (NTRA) PT Raised to $195 at TD Cowen; 'Solid Momentum Set to Continue'
-
Is Trump 2.0 good or bad for healthcare stocks?
-
Natera (NTRA) Issues Statement on Guardant Health Litigation
-
Natera (NTRA) PT Raised to $200 at Piper Sandler
-
Natera (NTRA) PT Raised to $175 at TD Cowen
-
Natera (NTRA) PT Raised to $160 at Baird
-
Natera (NTRA) PT Raised to $182 at Jefferies
-
Natera (NTRA) Tops Q3 EPS by 31c, Beats on Revenue; Offers FY24 Revenue Guidance
-
Natera (NTRA) Tops Q3 EPS by 31c; raises outlook
-
Natera (NTRA) PT Raised to $150 at Canaccord Genuity
-
Natera (NTRA) Reports Court Ordered Permanent Injunction Against NeoGenomics' Accused RaDaR Assay
-
Piper Sandler Reiterates Overweight Rating on Natera (NTRA)
-
TD Cowen Reiterates Buy Rating on Natera (NTRA)
-
Canaccord Genuity Reiterates Buy Rating on Natera (NTRA)
-
Natera (NTRA) PT Raised to $145 at Canaccord Genuity
-
Natera (NTRA) PT Raised to $145 at TD Cowen
-
Natera (NTRA) PT Raised to $120 at Baird
-
Natera (NTRA) Tops Q2 EPS by 39c, provides guidance
-
TD Cowen Reiterates Buy Rating on Natera (NTRA)
-
Piper Sandler Reiterates Overweight Rating on Natera (NTRA)
-
These stocks offer you exposure to rising demand for fertility treatment – Barclays
-
Natera (NTRA) Announces DECIPHER Phase 2 Trial
-
Wolfe Research Reiterates Outperform Rating on Natera (NTRA)
-
Cabot Wealth shares top 10 stocks picks for this week

